New immunotherapy shows reduction in tumor size for NSCLC patients
Last updated: 01 November 2019
You can legally access new medicines, even if they are not approved in your country.
Learn how
M7824, an immunotherapy candidate being developed by EMD Serono, reduced tumor size in a significant number of patients with advanced non-small cell lung cancer (NSCLC), Phase 1 data shows. It’s believed that this immunotherapy and its dual approach to fighting cancer will be a notable complement to existing immuno-oncology treatments.
Find the full press statement and further information in this article.